ALG-055009, Publications

Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia

ALG-000184, Publications

Preclinical Antiviral, Pharmacological and Toxicological Characteristics of ALG-000184, a Prodrug of the Novel HBV Capsid Assembly Modulator ALG‑001075

ALG-000184, Publications

The Capsid Assembly Modulator ALG-000184 Dosed for 28 Days Was Well Tolerated and Rapidly Reduced Viral Markers in Subjects with Chronic Hepatitis B, Including HBsAg in a Subset of HBeAg Positive Subjects with Elevated Baseline ALT

Other, Publications

Preclinical Profile of ALG-125755, a GalNAc-siRNA Targeting HBV

ALG-000184, Publications

ALG-000184, a Capsid Assembly Modulator, Demonstrates Superior Antiviral Activity in Combination with Entecavir Compared to Entecavir in HBeAg Positive Subjects with Chronic Hepatitis B infection

Publication, Publications

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir

ALG-097558, Publications

Preclinical Evaluation of ALG-097558:A Novel, Orally Bioavailable Pan-Coronavirus 3CLpro Inhibitor for the Treatment of COVID-19

ALG-000184, Publications

The Prodrug of a Novel Capsid Assembly Modulator (CAM), ALG-000184, Demonstrates a Favorable Nonclinical Toxicokinetic and Toxicology Profile for the Treatment of Chronic Hepatitis B (CHB)

Preclinical, Publications

Discovery of Liver-targeted Oral PD-L1 Small Molecule Inhibitors for the Treatment of Chronic Hepatitis B and Liver Cancers

ALG-000184, Publications

Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)